Univercells S.A.

Univercells S.A. is a Belgian biotechnology company founded in 2013 and headquartered in Charleroi, Belgium. It develops and supplies innovative biomanufacturing platforms, equipment, and technologies focused on cost-effective production of vaccines, biologics, viral vectors, and mRNA-based therapeutics.

The company's core offerings include process intensification solutions such as the NevoLine upstream platforms and scale-X fixed-bed bioreactors. These enable high-density cell culture, integrated clarification and capture, automated operations, and significantly reduced manufacturing footprints, capital costs, and cost of goods. Services encompass technology transfer, process development, and support for viral vector and mRNA platforms, positioning the firm as a key partner for CDMO operations and vaccine facility projects globally.

Univercells primarily operates from Belgium with international reach through partnerships, including with organizations like the Bill & Melinda Gates Foundation. It has supplied technology for biologics manufacturing in various regions, including emerging markets. Following group restructuring, Univercells acts as a holding company with independent entities handling CDMO services (e.g., Exothera), RNA production (e.g., Quantoom Biosciences), and related activities. The company has encountered financial difficulties, including restructuring and the opening of bankruptcy proceedings in late 2025, yet remains referenced in ongoing industry projects as of 2026.

In the biopharmaceutical industry, Univercells is recognized for advancing accessible, scalable manufacturing solutions that address global health needs for affordable vaccines and advanced therapies.